Full text is available at the source.
Abstract
Postmarketing safety signals and medication-use risks associated with GLP-1 receptor agonists and tirzepatide have been characterized.
- Postmarketing safety signals for GLP-1 receptor agonists and tirzepatide have been identified.
- Medication-use risks related to these treatments in diabetes and obesity care are highlighted.
- The analysis utilized an integrated framework for pharmacovigilance and regulatory assessment.
- Findings may inform future regulatory and clinical decision-making regarding these medications.
Simplified